Development of improved formulations or delivery systems could potentially enhance therapeutic efficacy, reduce dosing frequency, or improve patient compliance with treatment protocols
Some clinicians use TA1 offlabel to support patients with autoimmune disease, citing its ability to modulate the immune system without broad suppression
The approval process is rigorous, involving extensive clinical trials to ensure both safety and efficacy
It supports collagen production for healthy skin and tissues, improves iron absorption, and enhances heart health by lowering blood pressure and cholesterol
Many clients report noticeable improvements in energy, mood, and clarity within hours of treatment
Released glutamate must be rapidly removed to avoid continuous stimulation and excitotoxicity [43, 44] (see also glutamate-induced excitotoxicity)